CA3219484A1 - Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder - Google Patents
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder Download PDFInfo
- Publication number
- CA3219484A1 CA3219484A1 CA3219484A CA3219484A CA3219484A1 CA 3219484 A1 CA3219484 A1 CA 3219484A1 CA 3219484 A CA3219484 A CA 3219484A CA 3219484 A CA3219484 A CA 3219484A CA 3219484 A1 CA3219484 A1 CA 3219484A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- seq
- methylation
- naltrexone
- slc6a3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192952P | 2021-05-25 | 2021-05-25 | |
| US63/192,952 | 2021-05-25 | ||
| PCT/US2022/030946 WO2022251375A2 (en) | 2021-05-25 | 2022-05-25 | Epigenetic moderators of naltrexone efficacy efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219484A1 true CA3219484A1 (en) | 2022-12-01 |
Family
ID=84230385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219484A Pending CA3219484A1 (en) | 2021-05-25 | 2022-05-25 | Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220389509A1 (https=) |
| EP (1) | EP4326904A4 (https=) |
| JP (1) | JP2024521754A (https=) |
| CA (1) | CA3219484A1 (https=) |
| WO (1) | WO2022251375A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025010067A1 (en) * | 2023-07-06 | 2025-01-09 | Smith Genetics Research Llc | Treatment of autonomic dysfunction resulting from opioid use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| US20090307179A1 (en) * | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| US8815779B2 (en) * | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
| US20120142543A1 (en) * | 2010-11-29 | 2012-06-07 | Kenneth Blum | Methods to assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors utilizing expression profiling |
| US20140274763A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to pain treatments |
| US20180369238A1 (en) * | 2017-06-23 | 2018-12-27 | Musc Foundation For Research Development | Dopamine agonists in treating alcohol use disorders associated with dopamine receptor activity |
| US20180371542A1 (en) * | 2017-06-26 | 2018-12-27 | Musc Foundation For Research Development | Opioid receptor blockade in treating alcohol use disorders |
-
2022
- 2022-05-25 JP JP2023572581A patent/JP2024521754A/ja active Pending
- 2022-05-25 WO PCT/US2022/030946 patent/WO2022251375A2/en not_active Ceased
- 2022-05-25 EP EP22812081.2A patent/EP4326904A4/en active Pending
- 2022-05-25 US US17/824,784 patent/US20220389509A1/en active Pending
- 2022-05-25 CA CA3219484A patent/CA3219484A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326904A4 (en) | 2025-03-26 |
| US20220389509A1 (en) | 2022-12-08 |
| WO2022251375A8 (en) | 2024-01-04 |
| WO2022251375A3 (en) | 2023-01-05 |
| EP4326904A2 (en) | 2024-02-28 |
| WO2022251375A2 (en) | 2022-12-01 |
| JP2024521754A (ja) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5881420B2 (ja) | 自閉症関連遺伝子マーカー | |
| Proudnikov et al. | Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes | |
| JP2014518069A (ja) | 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー | |
| US20120053070A1 (en) | Genetic Risk Analysis In Reward Deficiency Syndrome | |
| EP2061910B1 (en) | Prognostic method | |
| WO2012030983A2 (en) | Variability single nucleotide polymorphisms linking stochastic epigenetic variation and common disease | |
| US20220389509A1 (en) | Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder | |
| US20150292016A1 (en) | Novel markers for mental disorders | |
| US20110287417A1 (en) | Predicting a response to risperidone | |
| Smit et al. | BEGAIN: a novel imprinted gene that generates paternally expressed transcripts in a tissue-and promoter-specific manner in sheep | |
| US20020045171A1 (en) | Method of profiling genes as risk factors for attention deficit hyperactivity disorder | |
| WO2010007063A2 (en) | Method of diagnosing dyslexia | |
| US20050255507A1 (en) | Cytogenetically determined diagnosis and prognosis of proliferative disorders | |
| KR102650359B1 (ko) | 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법 | |
| KR102473350B1 (ko) | 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커 | |
| KR102477502B1 (ko) | 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커 | |
| KR102473348B1 (ko) | 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커 | |
| JP2006296270A (ja) | Ｐｒｋａａ２遺伝子多型による２型糖尿病発症素因の検出方法 | |
| Alrfooh | DNA methylation signature: as a potential biomarker for addiction and psychiatric disorders | |
| JP2007517511A (ja) | ヒトチオプリンｓ−メチルトランスフェラーゼ欠損に関連するハプロタイプおよび多型 | |
| Alshafai | Family-based investigation of the genetics and epigenetics of obesity in Qatar | |
| WO2011148379A2 (en) | Antipsychotic-induced parkinsonism genotypes and methods of using same | |
| WO2009036513A1 (en) | Diagnostic and therapeutic protocols | |
| Perrotta et al. | Molecular diagnostics in hemostatic disorders | |
| EP2576821A1 (en) | Biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R124 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF COMMON REPRESENTATIVE REQUEST Effective date: 20240812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20241202 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250430 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |